TNFSF10 and neoplasm: In short, these findings suggest that concomitant therapy with Ad-ΔB/TRAIL plus Ad-ΔB/IL-12 was significantly associated with generation of anti-tumour specific immune response as well as anti-angiogenesis and antitumor vasculature effect than therapy with Ad-ΔB.